Claims
- 1. A method for treating a mucus secretion of a patient, the method comprising the step of administering to a patient an effective amount of a botulinum toxin in order to reduce a mucus secretion of the patient, wherein the mucus secretion is not a symptom of rhinorrhea.
- 2. The method of claim 1, wherein the mucus secretion is a cholinergic influenced mucus secretion.
- 3. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A.
- 4. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
- 5. The method of claim 1, wherein the botulinum toxin is administered in an amount of between 0.01 units and 5000 units.
- 6. The method of claim 1, wherein the botulinum toxin is administered in an amount of between 0.01 unit and 500 units.
- 7. A method for treating a cholinergic influenced mucus secretion of a human patient, the method comprising the step of administering to a human patient a therapeutically effective amount of botulinum toxin type A in order to reduce the mucus secretion, wherein the mucus secretion is not a symptom of rhinorrhea.
- 8. A method for treating a mucus secreting gland, the method comprising the step of administering to a mucus secreting gland a botulinum toxin thereby reducing a mucus secretory activity of the gland, wherein the mucus secretion is not a symptom of rhinorrhea.
- 9. The method of claim 8, wherein the gland is an excessively secreting mucus gland.
- 10. The method of claim 8, wherein the mucus gland is influenced by the cholinergic nervous system.
- 11. The method of claim 8, wherein the botulinum toxin is administered by injection into the mucus gland or into the local area of the mucus gland.
- 12. The method of claim 8, wherein the botulinum toxin is botulinum toxin type A.
- 13. The method of claim 8, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
- 14. The method of claim 8, wherein the botulinum toxin is administered in an amount of between 0.01 units and 5000 units.
- 15. The method of claim 8, wherein the botulinum toxin is administered in an amount of between 0.01 units and 500 units.
- 16. A method for treating an excessively secreting mucus gland, the method comprising the step of injecting an excessively secreting, cholinergic nervous system influenced mucus gland or local mucus gland area of a human patient with a therapeutically effective amount of botulinum toxin type A in order to reduce the excessive mucus gland secretion, wherein the mucus secretion is not a symptom of rhinorrhea.
CROSS-REFERENCE
[0001] This application is a continuation-in-part of Ser. No. 09/487,477, filed Jan. 19, 2000, which is a divisional of Ser. No. 08/627,118, filed Apr. 3, 1996, which is a continuation of Ser. No. 08/173,996, filed Dec. 28, 1993, now abandoned.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08627118 |
Apr 1996 |
US |
Child |
09487477 |
Jan 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08173996 |
Dec 1993 |
US |
Child |
08627118 |
Apr 1996 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09487477 |
Jan 2000 |
US |
Child |
10008722 |
Dec 2001 |
US |